Body mass index, HbA1c and serum C-reactive protein are predictors of secondary failure in infliximab continuance for Japanese psoriasis patients: A hospital-based retrospective case-control study.

Szczegóły
Abstrakt

Tytuł:: Body mass index, HbA1c and serum C-reactive protein are predictors of secondary failure in infliximab continuance for Japanese psoriasis patients: A hospital-based retrospective case-control study.
Autorzy:: Terui H; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Asano M; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shimada-Omori R; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tsuchiyama K; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takahashi T; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Nasu-Tamabuchi M; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hagiwara-Takita A; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kusakari Y; Dermatology, Sendai City Hospital, Sendai, Japan.
Ohtani T; Miyachiyo Dermatology Clinic, Sendai, Japan.
Aiba S; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yamasaki K; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Źródło:: The Journal of dermatology [J Dermatol] 2021 Nov; Vol. 48 (11), pp. 1719-1723. Date of Electronic Publication: 2021 Aug 06.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: London : Wiley-Blackwell
Original Publication: Tokyo, Japanese Dermatological Association, <-2005>
MeSH Terms:: C-Reactive Protein*
Psoriasis*/drug therapy
Body Mass Index ; Case-Control Studies ; Glycated Hemoglobin ; Hospitals ; Humans ; Infliximab/therapeutic use ; Japan ; Retrospective Studies ; Treatment Outcome
References:: Lebwohl M. Psoriasis. Lancet. 2003;361:1197-204.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496-509.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-85.
Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385-422.
Zweegers J, van den Reek J, van den Kerkhof P, Otero ME, Kuijpers A, Koetsier M, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175:340-7.
Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59:40-9.
Kimura Y, Shimada-Omori R, Takahashi T, Tsuchiyama K, Kusakari Y, Yamasaki K, et al. Therapeutic drug monitoring of patients with psoriasis during tumour necrosis factor (TNF)-alpha antagonist treatment using a novel interleukin-8 reporter cell line. Br J Dermatol. 2016;175:979-87.
Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159:342-50.
Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci. 2009;55:62-3.
Shibata S, Tada Y, Hau C, Tatsuta A, Yamamoto M, Kamata M, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol. 2011;164:667-70.
Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol. 2008;159:1207-8.
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377-90.
Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149:84-91. https://doi.org/10.1001/2013.jamadermatol.406.
Coto-Segura P, Eiris-Salvado N, González-Lara L, Queiro-Silva R, Martinez-Camblor P, Maldonado-Seral C, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol. 2013;169:783-93.
Borst SE. The role of TNF-alpha in insulin resistance. Endocrine. 2004;23:177-82.
Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003;52:1779-85.
Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303-7.
Asahina A, Umezawa Y, Yanaba K, Nakagawa H. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics. J Dermatol. 2016;43:779-84.
Takahashi H, Iinuma S, Honma M, Iizuka H. Increased serum C-reactive protein level in Japanese patients of psoriasis with cardio- and cerebrovascular disease. J Dermatol. 2014;41:981-5.
Terui H, Yamasaki K, Hagiwara-Takita A, Shimada-Omori R, Tsuchiyama K, Saito-Nanjo Y, et al. Pediatric psoriasis induced by HLA-B46-Cw1 haplotype: A retrospective study of psoriasis onset after hematopoietic stem cell transplantation. J Dermatol. 2021. https://doi.org/10.1111/1346-8138.15953.
Umezawa Y, Nobeyama Y, Hayashi M, Fukuchi O, Ito T, Saeki H, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40:1008-13.
Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164:1091-6.
Menting SP, Sitaram AS, Bonnerjee-van der Stok HM, de Rie MA, Hooft L, Spuls PI. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. Br J Dermatol. 2014;171:875-83.
Contributed Indexing:: Keywords: CRP; HbA1c; TNF; adipocyte; body mass index; infliximab; psoriasis
Substance Nomenclature:: 0 (Glycated Hemoglobin A)
9007-41-4 (C-Reactive Protein)
B72HH48FLU (Infliximab)
Entry Date(s):: Date Created: 20210806 Date Completed: 20211103 Latest Revision: 20221207
Update Code:: 20240105
DOI:: 10.1111/1346-8138.16096
PMID:: 34355429
: Czasopismo naukowe

Full Text Finder

Biologics has had a great impact on psoriasis treatment as well as the life of psoriasis patients. Infliximab (IFX), one of the biologics targeting tumor necrosis factor (TNF), is the first of the biologics introduced to Japanese psoriasis patients. Many patients had benefits of IFX from initial applications and sustained remission of skin lesions and arthritis. Some, however, fall into so-called secondary failure, in which patients become less responsive to IFX when the treatment is repeated. The mechanism of secondary failure and the background of patients with secondary failure have not been completely elucidated. To address this issue, we retrospectively evaluated psoriasis patients treated with IFX in our department. In this retrospective, single-center, case-control study based on the clinical record, a total of 34 patients were enrolled. We excluded 7 patients who discontinued IFX because of adverse events of IFX. We divided other 27 patients into two groups; 16 patients who kept using IFX (Continuance group); and 11 patients who switched to other treatments (Discontinuance group). Among various clinical features, body mass index (BMI), HbA1c, and serum CRP level were significantly higher in the Discontinuance group than the Continuance group. The results indicated that these three clinical features of BMI, HbA1c and serum CRP level before treatment are the predictors of successful IFX treatment and suggest that improvement of metabolic conditions contributes to avoiding secondary failure and discontinuance of IFX.
(© 2021 Japanese Dermatological Association.)

Informacja